Loading...
Docetaxel for hormone-naive prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden
Ali, Adnan Ingleby, FC Hoyle, Alex P Calvert, J Attard, G Chowdhury, S Dearnaley, D Douis, H Gillessen, Silke
Ali, Adnan
Ingleby, FC
Hoyle, Alex P
Calvert, J
Attard, G
Chowdhury, S
Dearnaley, D
Douis, H
Gillessen, Silke
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Clarke NW, Ali A, Ingleby FC, Hoyle A, Calvert J, Attard G, et al. 844O Docetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden. Annals of Oncology. 2019;30(Supplement_5).